HRMY logo

HRMYHarmony Biosciences Holdings Inc

$35.48
$1.38
(4.05%)
Today
Closed $35.48
$0.3185
(0.90%)
After Hours
Updated: 07:53 PM EDT
EarningsAug 4
Mkt Cap$1.97B
Vol1.86M
News
all
press releases
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?
ANIP trades at 9.75x forward earnings after raising 2026 guidance, but investors must weigh Cortrophin-led growth against competition and customer concentration.
Zacks
News Placeholder
More News
News Placeholder
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push
ANIP expands Cortrophin into acute gout flares with a 90-person sales force as investors watch adoption, spending and 2026 milestones.
Zacks
News Placeholder
Harmony Biosciences Holdings (HRMY): One of the Best Stocks to Buy According to AI
Harmony Biosciences Holdings (HRMY): One of the Best Stocks to Buy According to AI...
Yahoo! Finance: News
News Placeholder
Harmony Biosciences to Participate in Upcoming Investor Conferences
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat: June 9, 2026, at 8:40 a.m. ET Location: Miami, FL Oppenheimer CNS...
Business Wire
News Placeholder
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.
Zacks
News Placeholder
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised
ANI Pharmaceuticals tops Q1 estimates as Cortrophin Gel sales climb 42%, prompting it to raise the 2026 revenue, EBITDA and EPS outlook.
Zacks
News Placeholder
Harmony Biosciences Holdings, Inc. (HRMY) Q1 Earnings and Revenues Miss Estimates
Harmony Biosciences (HRMY) delivered earnings and revenue surprises of -27.94% and -3.18%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass Estimates
Royalty Pharma (RPRX) delivered earnings and revenue surprises of +6.56% and +3.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice
Harmony Biosciences (HRMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks
News Placeholder
HRMY or ARGX: Which Is the Better Value Stock Right Now?
HRMY vs. ARGX: Which Stock Is the Better Value Option?
Zacks
<
1
2
...
>

Advertisement|Remove ads.